C R Antonescu

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Dedifferentiation in Gastrointestinal Stromal Tumor to an Anaplastic KIT-negative Phenotype: A Diagnostic Pitfall: Morphologic and Molecular Characterization of 8 Cases Occurring Either De Novo or After Imatinib Therapy
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center Weill Medical College of Cornell University, New York, NY Surgical Pathology, Brigham and Women s Hospital Massachusetts General Hospital, Boston, MA Treviso General Hospital, Treviso, Italy Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China
    Am J Surg Pathol 37:385-92. 2013
  2. ncbi Gastrointestinal stromal tumors
    Cristina Antonescu
    Memorial Sloan Kettering Cancer Center, New York, NY, 10021, USA
    Curr Top Microbiol Immunol 355:41-57. 2012
  3. ncbi SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors
    Antoine Italiano
    Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BMC Cancer 12:408. 2012
  4. ncbi The GIST paradigm: lessons for other kinase-driven cancers
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Pathol 223:251-61. 2011
  5. ncbi Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases
    C R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 7:3977-87. 2001
  6. ncbi Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mod Pathol 21:S31-6. 2008
  7. ncbi EWSR1-POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty-six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York City, NY 10021, USA
    Genes Chromosomes Cancer 49:1114-24. 2010
  8. ncbi Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site
    Cristina R Antonescu
    Departments of Pathology, Memorial Sloan Kettering Cancer Center, and Molecular Biology, Computational Biology Center, Sloan Kettering Institute, New York, New York 10021, USA
    Clin Cancer Res 10:3282-90. 2004
  9. ncbi Targeted therapies in gastrointestinal stromal tumors
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Semin Diagn Pathol 25:295-303. 2008
  10. ncbi The rise and fall of malignant fibrous histiocytoma
    Robert A Erlandson
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Ultrastruct Pathol 28:283-9. 2004

Detail Information

Publications94

  1. ncbi Dedifferentiation in Gastrointestinal Stromal Tumor to an Anaplastic KIT-negative Phenotype: A Diagnostic Pitfall: Morphologic and Molecular Characterization of 8 Cases Occurring Either De Novo or After Imatinib Therapy
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center Weill Medical College of Cornell University, New York, NY Surgical Pathology, Brigham and Women s Hospital Massachusetts General Hospital, Boston, MA Treviso General Hospital, Treviso, Italy Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China
    Am J Surg Pathol 37:385-92. 2013
    ..This phenomenon is not related to additional KIT mutations, but might be secondary to genetic instability, either represented by loss of heterozygosity or low level of KIT amplification...
  2. ncbi Gastrointestinal stromal tumors
    Cristina Antonescu
    Memorial Sloan Kettering Cancer Center, New York, NY, 10021, USA
    Curr Top Microbiol Immunol 355:41-57. 2012
    ..This review summarizes the recent knowledge on targeted therapy in GIST, based on the central role of KIT oncogenic activation, as well as discussing mechanisms of resistance...
  3. ncbi SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors
    Antoine Italiano
    Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BMC Cancer 12:408. 2012
    ..A recent report identified four non-syndromic, KIT/PDGFRA WT GIST harboring compound heterozygous or homozygous mutations in SDHA encoding the main subunit of the SDH complex II...
  4. ncbi The GIST paradigm: lessons for other kinase-driven cancers
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Pathol 223:251-61. 2011
    ..Other broad therapeutic strategies could include combination of kinase inhibitors with targeting KIT downstream targets, such as PI3-K or MAPK/MEK inhibitors...
  5. ncbi Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases
    C R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 7:3977-87. 2001
    ..We also analyzed P53 status, because this parameter has been found to have a significant prognostic impact in other sarcomas with chromosomal translocations...
  6. ncbi Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mod Pathol 21:S31-6. 2008
    ..The success GIST story based on targeted molecular paradigm may be applied in other imatinib-responsive sarcoma, such as dermatofibrosarcoma protuberans...
  7. ncbi EWSR1-POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty-six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York City, NY 10021, USA
    Genes Chromosomes Cancer 49:1114-24. 2010
    ..These findings do not support a pathogenetic relationship between soft tissue ME tumors and their salivary gland counterparts...
  8. ncbi Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site
    Cristina R Antonescu
    Departments of Pathology, Memorial Sloan Kettering Cancer Center, and Molecular Biology, Computational Biology Center, Sloan Kettering Institute, New York, New York 10021, USA
    Clin Cancer Res 10:3282-90. 2004
    ..We tested the hypothesis that the gene expression profile in GISTs might be related to KIT genotype and possibly to other clinicopathological factors...
  9. ncbi Targeted therapies in gastrointestinal stromal tumors
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Semin Diagn Pathol 25:295-303. 2008
    ..In addition, we provide an updated discussion on diagnostic pitfalls, including changes secondary to imatinib response and resistance...
  10. ncbi The rise and fall of malignant fibrous histiocytoma
    Robert A Erlandson
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Ultrastruct Pathol 28:283-9. 2004
    ..On the basis of these findings, we propose a new classification for the above subtypes of so-called malignant fibrous histiocytoma, the majority of which are variants of pleomorphic fibrosarcoma...
  11. ncbi Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, and Molecular Biology Program, Sloan Kettering Institute, New York, New York, 10021, USA
    Clin Cancer Res 9:3329-37. 2003
    ..The impact of KIT mutation in other regions, such as the extracellular or kinase domains, is not well-defined and fewer than 30 cases have been published to date...
  12. ncbi EWSR1-ATF1 fusion is a novel and consistent finding in hyalinizing clear-cell carcinoma of salivary gland
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Genes Chromosomes Cancer 50:559-70. 2011
    ..The distinction from MEC is particularly important, as conventional MEC grading schemes overgrade these indolent HCCCs, potentially impacting on treatment...
  13. ncbi Gastrointestinal stromal tumor (GIST) pathogenesis, familial GIST, and animal models
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Semin Diagn Pathol 23:63-9. 2006
    ..This is a US government work. There are no restrictions on its use...
  14. ncbi KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer, New York, New York 10065, USA
    Cancer Res 69:7175-9. 2009
    ..These data provide a basis for the activity of vascular endothelial growth factor receptor-directed therapy in the treatment of primary and radiation-induced AS...
  15. ncbi L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 121:257-64. 2007
    ..These results suggest that a subset of anal melanomas show activating KIT mutations, which are susceptible for therapy with specific kinase inhibitors...
  16. ncbi Spectrum of low-grade fibrosarcomas: a comparative ultrastructural analysis of low-grade myxofibrosarcoma and fibromyxoid sarcoma
    Cristina R Antonescu
    Department of Pathology and Electron Microscopy Laboratory, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Ultrastruct Pathol 28:321-32. 2004
    ..The very long, thin cell processes, sometimes associated with pinocytotic vesicles, were reminiscent of perineurioma ultrastructure...
  17. ncbi The role of genetic testing in soft tissue sarcoma
    C R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Histopathology 48:13-21. 2006
    ..This review focuses on the applicability of genetic testing in the diagnosis and prognosis of soft tissue sarcomas, and gives a realistic appraisal of the ancillary role of molecular techniques, including its advantages and limitations...
  18. ncbi Fibrosarcoma mimicking plasmacytoma or carcinoma: an ultrastructural study of 4 cases
    C R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ultrastruct Pathol 25:31-7. 2001
    ..These findings broaden the spectrum of fibroblastic cell variants in neoplasia...
  19. ncbi EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Genes Chromosomes Cancer 46:1051-60. 2007
    ..Thus, identical fusions involving ATF1 and CREB1 are found in two distinct sarcomas, which may be able to transform two different types of mesenchymal precursor cells, unlike most other sarcoma gene fusions...
  20. ncbi Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Genes Chromosomes Cancer 50:757-64. 2011
    ..FISH analysis for TGFBR3 and MGEA5 rearrangements can be applied as a reliable diagnostic molecular test when confronted with limited material or a challenging diagnosis...
  21. ncbi Sclerosing epithelioid fibrosarcoma: a study of 16 cases and confirmation of a clinicopathologically distinct tumor
    C R Antonescu
    Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Am J Surg Pathol 25:699-709. 2001
    ....
  22. ncbi Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
    Cristina R Antonescu
    Department of Pathology, Sloan Kettering Institute, New York, New York, USA
    Clin Cancer Res 11:4182-90. 2005
    ..That acquired resistance to imatinib in GIST commonly occurs via secondary gene mutation in the KIT kinase domain has implications for strategies to delay or prevent imatinib resistance and to employ newer targeted therapies...
  23. ncbi Molecular profiling in the diagnosis and treatment of high grade sarcomas
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ultrastruct Pathol 32:37-42. 2008
    ..This review includes a brief description of the microarray methodology and data analysis, followed by few examples of the recent applications of gene expression in the diagnosis, classification, and treatment of sarcomas...
  24. ncbi Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents
    P Argani
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland 21231 2410, USA
    Am J Pathol 159:179-92. 2001
    ..Finally, the finding of distinctive tumors being associated with balanced and unbalanced forms of the same translocation is to our knowledge, unprecedented...
  25. ncbi Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity
    J J Lewis
    Departments of Surgery, Biostatistics, and Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 18:2087-94. 2000
    ..The objective of this study was to determine independent prognostic factors of primary synovial sarcoma localized to the extremity...
  26. ncbi Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature
    Sonam Prakash
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Pediatr Hematol Oncol 27:179-87. 2005
    ..The distinct gene expression profile suggests avenues for investigation of pathogenesis and potential therapeutic strategies...
  27. ncbi Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors
    Narasimhan P Agaram
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:170-81. 2007
    ..Our goal was to investigate the spectrum of pathologic response and molecular alterations in a group of GIST patients, clinically defined as having imatinib-stable/imatinib-responsive lesions, who underwent surgical resection...
  28. ncbi Molecular characterization of pediatric gastrointestinal stromal tumors
    Narasimhan P Agaram
    Department of Pathology, Sloan Kettering Institute, New York, New York 10021, USA
    Clin Cancer Res 14:3204-15. 2008
    ....
  29. ncbi Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor
    Tianhua Guo
    Department of Pathology, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Clin Cancer Res 13:4874-81. 2007
    ....
  30. ncbi Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma
    Tadahiko Kubo
    Orthopedic Surgery Service, Memorial Sloan Kettering Cancer Center, Weil Medical College of Cornell University, New York, New York, USA
    Cancer 112:2119-29. 2008
    ....
  31. ncbi Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor
    J A Bridge
    Department of Pathology, Center for Human Molecular Genetics, 983135 University of Nebraska Medical Center, Omaha, NE 68198, USA
    Am J Pathol 159:411-5. 2001
    ..One of these cases exhibited a 2;17 translocation in addition to other karyotypic anomalies [46,XX,t(2;17)(p23;q23),add(16)(q24)]...
  32. ncbi Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors
    Narasimhan P Agaram
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Genes Chromosomes Cancer 47:853-9. 2008
    ..A secondary V600E BRAF mutation could represent an alternative mechanism of imatinib resistance. Kinase inhibitors targeting BRAF may be effective therapeutic options in this molecular GIST subset...
  33. ncbi Characterization of molecular abnormalities in human fibroblastic neoplasms: a model for genotype-phenotype association in soft tissue tumors
    A Hoos
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 61:3171-5. 2001
    ..pRB and Ki-67 status may be useful to predict recurrence in certain subsets of patients...
  34. ncbi The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25
    M Ladanyi
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Oncogene 20:48-57. 2001
    ..Oncogene (2001) 20, 48 - 57...
  35. ncbi Soft tissue tumors of the abdominal wall: analysis of disease patterns and treatment
    A Stojadinovic
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Arch Surg 136:70-9. 2001
    ..Complete surgical resection is the recommended treatment approach to achieve local control. Stratification by prognostic factors will facilitate selection of patients with STS for adjuvant systemic therapies...
  36. ncbi ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours
    Ping Chi
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Nature 467:849-53. 2010
    ..It also represents a novel mechanism of oncogenic transcription factor activation...
  37. ncbi Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor
    Ferdinand Rossi
    Department of Developmental Biology, Computational Biology Center, and Molecular Cytology Facility, Sloan Kettering Institute, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 103:12843-8. 2006
    ....
  38. ncbi Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance
    Tianhua Guo
    Departments of Pathology, Medicine, and Surgery, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, NY 10021, USA
    Clin Cancer Res 15:6862-70. 2009
    ..The clinical benefit of sunitinib is genotype-dependent in regards to both primary and secondary mutations, with GIST patients harboring the KIT(AY502-3ins) exon 9 mutation being the most sensitive...
  39. ncbi Primary fibrosarcoma and malignant fibrous histiocytoma of bone--a comparative ultrastructural study: evidence of a spectrum of fibroblastic differentiation
    C R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ultrastruct Pathol 24:83-91. 2000
    ..These findings support the hypothesis that the fibroblast and its variants are the predominant cell types found in these tumors, suggesting that the diagnostic entity MFH should be classified as a pleomorphic fibrosarcoma...
  40. ncbi Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression
    Bernadette Liegl
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am J Surg Pathol 33:218-26. 2009
    ..The rhabdomyoblastic differentiation can represent a diagnostic pitfall. The molecular mechanisms for this form of TKI-resistant clonal evolution remain to be determined...
  41. ncbi Outcome of metastatic GIST in the era before tyrosine kinase inhibitors
    Jason S Gold
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Ann Surg Oncol 14:134-42. 2007
    ..Treatment of metastatic GIST with imatinib mesylate results in a 2-year survival of approximately 72%. The outcome of patients with metastatic GIST not treated with tyrosine kinase inhibitors is not well defined...
  42. ncbi Comparative ultrastructural analysis and KIT/PDGFRA genotype in 125 gastrointestinal stromal tumors
    Narasimhan P Agaram
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Ultrastruct Pathol 30:443-52. 2006
    ..GISTs showing both NS-G and microtubules were associated with KIT exon 11 genotype and spindle cell morphology. PDGFRA mutated cases were associated with gastric location, predominantly epithelioid morphology and lacked NS-G...
  43. ncbi Detection of clinically amelanotic malignant melanoma and assessment of its margins by in vivo confocal scanning laser microscopy
    K J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Arch Dermatol 137:923-9. 2001
    ..Near-infrared confocal scanning laser microscopy (CSLM) represents a novel imaging technique for in vivo microscopic analysis of skin lesions, including pigmented lesions...
  44. ncbi Clinicopathologic analysis of patients with adult rhabdomyosarcoma
    W G Hawkins
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer 91:794-803. 2001
    ..All histologic subtypes of RMS are aggressive malignancies with poor disease specific survival despite aggressive multimodality management...
  45. ncbi Chordoma and chondrosarcoma gene profile: implications for immunotherapy
    Joseph H Schwab
    Department of Surgery, Orthopedic Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immunol Immunother 58:339-49. 2009
    ..In conclusion, chordomas and chondrosarcomas share a similar gene expression profile of up-regulated extracellular matrix genes. HMW-MAA represents a potential useful target to apply immunotherapy to these tumors...
  46. ncbi Molecular variability of TLS-CHOP structure shows no significant impact on the level of adipogenesis: a comparative ultrastructural and RT-PCR analysis of 14 cases of myxoid/round cell liposarcomas
    Hsuan-Ying Huang
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Ultrastruct Pathol 27:217-26. 2003
    ..These findings cannot substantiate the hypothesis that the molecular variability of fusion transcripts has a biological impact on adipogenesis of MLS, and other factors might be implicated in their level of differentiation...
  47. ncbi Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk
    Kimberly Moore Dalal
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 244:381-91. 2006
    ..DSS nomograms aid in more accurate counseling of patients, identification of patients appropriate for adjuvant therapy, and stratification of patients for clinical trials and molecular analysis...
  48. ncbi Skeletal metastases in myxoid liposarcoma: an unusual pattern of distant spread
    Joseph H Schwab
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg Oncol 14:1507-14. 2007
    ..Anecdotal evidence, mainly supported by isolated case reports, suggests that a subset of these patients also develop bone metastasis, especially within the spine, which was previously under-appreciated...
  49. ncbi EWS-CREB1: a recurrent variant fusion in clear cell sarcoma--association with gastrointestinal location and absence of melanocytic differentiation
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, and Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
    Clin Cancer Res 12:5356-62. 2006
    ..Thus, evidence of melanocytic lineage or differentiation is not a necessary feature of sarcomas with gene fusions involving CREB family members...
  50. ncbi Molecular diagnosis of clear cell sarcoma: detection of EWS-ATF1 and MITF-M transcripts and histopathological and ultrastructural analysis of 12 cases
    Cristina R Antonescu
    Department of Patholog, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Mol Diagn 4:44-52. 2002
    ..These data confirm that EWS-ATF1 detection can be used as a highly sensitive diagnostic test for CCS and that CCS expresses the melanocyte-specific form of the MITF transcript, further supporting its genuine melanocytic differentiation...
  51. ncbi Chordoid glioma: report of a case with unusual histologic features, ultrastructural study and review of the literature
    Jeffrey J Raizer
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Neurooncol 63:39-47. 2003
    ..Treatment and long term outcome are limited but chordoid gliomas appear to be indolent lesions that may be cured with gross total resection...
  52. ncbi Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 6007, USA
    Int J Cancer 100:623-6. 2002
    ..Imatinib may be useful for patients with locally advanced DFSP, when other options for local therapy are limited...
  53. ncbi MAGE antigen expression in monophasic and biphasic synovial sarcoma
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Hum Pathol 33:225-9. 2002
    ..Our study demonstrates that MAGE is frequently and homogeneously expressed in synovial sarcomas of both morphological variants and both translocation types, making these tumors an attractive target for MAGE antigen-based immunotherapy...
  54. ncbi Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma
    Samuel Singer
    Sarcoma Biology Laboratory, Sarcoma Disease Management Program, Department of Surgery, Memorial Sloan Kettering Cancer Center and Genomics Core Facility, Sloan Kettering Institute, New York, NY 10021, USA
    Cancer Res 67:6626-36. 2007
    ..These results support the development of a clinical trial with MDM2 antagonists for liposarcoma subtypes which overexpress MDM2 and show the promise of using this expression dataset for new drug discovery in liposarcoma...
  55. ncbi The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147
    Marc Ladanyi
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Pathol 160:1215-21. 2002
    ..The possible basis for the overproduction or impaired surface localization of these proteins in ASPS remains unclear...
  56. ncbi Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling
    Neil H Segal
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:1775-81. 2003
    ..CCS/MSP also has typical melanoma features, including immunoreactivity for S100 and HMB45, pigmentation, MITF-M expression, and a propensity for regional lymph node metastases...
  57. ncbi Metastatic epithelioid gastrointestinal stromal tumor: yet another tumor with anemone cell features
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ultrastruct Pathol 27:95-100. 2003
    ....
  58. ncbi Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 245:347-52. 2007
    ..Nearly all tumors have an activating mutation in the KIT or, less often, PDGFRalpha, gene. Therapy with tyrosine kinase inhibitors benefits over 80% of patients with advanced GIST, but most patients eventually develop drug resistance...
  59. ncbi Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase
    Gunhild Sommer
    Developmental Biology Program, Sloan Kettering Institute, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 100:6706-11. 2003
    ..Importantly, these results demonstrate that constitutive Kit signaling is critical and sufficient for induction of GIST and hyperplasia of interstitial cells of Cajal...
  60. ncbi Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma
    Samuel Singer
    Sarcoma Disease Management Team, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10021, USA
    Ann Surg 238:358-70; discussion 370-1. 2003
    ..The aim of this study was to determine the pattern of recurrence and prognostic significance of histologic subtype in a large series of patients with primary retroperitoneal liposarcoma...
  61. ncbi Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas?
    Rebecca A Gladdy
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 1209, New York, NY 10065, USA
    J Clin Oncol 28:2064-9. 2010
    ..DSS in patients with primary RAS is significantly worse compared with sporadic STS independent of sarcoma histologic type...
  62. ncbi A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021 6007, USA
    Cancer 103:1431-8. 2005
    ..Based on evidence of activity in preclinical and Phase I studies, the authors undertook a study of bortezomib, a reversible proteasome inhibitor, for patients with metastatic sarcomas...
  63. ncbi Antigens recognized by autologous antibodies of patients with soft tissue sarcoma
    Neil H Segal
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 5:4. 2005
    ..Further studies of these selected novel STS antigens are warranted to identify and characterize potential antigen targets expressed by STS...
  64. ncbi Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 112:608-15. 2008
    ..Although the efficacy of tyrosine kinase inhibitors in metastatic GIST depends on tumor mutation status, there have been conflicting reports on the prognostic importance of KIT mutation in primary GIST...
  65. ncbi Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
    Robert G Maki
    Melanoma Sarcoma Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 909, New York, NY 10065, USA
    J Clin Oncol 27:3133-40. 2009
    ..Further evaluation of sorafenib in these and possibly other sarcoma subtypes appears warranted, presumably in combination with cytotoxic or kinase-specific agents...
  66. ncbi Distant metastasis in retroperitoneal dedifferentiated liposarcoma is rare and rapidly fatal: a clinicopathological study with emphasis on the low-grade myxofibrosarcoma-like pattern as an early sign of dedifferentiation
    Hsuan-Ying Huang
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, NY 10021, USA
    Mod Pathol 18:976-84. 2005
    ..Irrespective of the grade dedifferentiated liposarcoma with myxofibrosarcoma-like features should be closely monitored. Once metastases occur, they tend to follow a rapidly fatal course...
  67. ncbi Multiple gastrointestinal stromal tumors in type I neurofibromatosis: a pathologic and molecular study
    Rhonda K Yantiss
    Department of Pathology, UMass Memorial Health Care, Worcester, MA 01655, USA
    Mod Pathol 18:475-84. 2005
    ....
  68. ncbi Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics
    Neil H Segal
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 5:2. 2005
    ....
  69. ncbi Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients
    Marc Ladanyi
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 62:135-40. 2002
    ..In addition, the associations of SYT-SSX fusion type with patient sex and tumor epithelial differentiation point to interesting mechanistic biological differences...
  70. ncbi Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia
    Mark E Robson
    Clinical Genetics and Gastrointestinal Oncology Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 10:1250-4. 2004
    ..Preliminary correlations between the site of mutation and the clinical phenotype have been proposed, but the strength of these associations is not defined...
  71. ncbi Hepatic follicular dendritic cell sarcoma without Epstein-Barr virus expression
    Ulises Torres
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Arch Pathol Lab Med 129:1480-3. 2005
    ..Based on our experience and a review of the published reports, we summarize the clinical and pathologic features of hepatic follicular dendritic cell sarcoma and its surgical management...
  72. ncbi Metastatic thymic carcinoma in a digit: a case report
    F J Shannon
    Department of Surgery Orthopaedics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Hand Surg Am 25:1169-72. 2000
    ..Acrometastases are a rare but important clinical entity. We present the case of a 54-year-old man with a metastasis to a digit from a primary thymic carcinoma. The prognostic implications of such a diagnosis are discussed...
  73. ncbi Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7
    A A Jungbluth
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 94:252-6. 2001
    ..Our study shows that NY-ESO-1 is highly expressed in a homogeneous pattern in synovial sarcomas of both morphologic variants and both translocation types, making these tumors an attractive target for NY-ESO-1 antigen-based immunotherapy...
  74. ncbi Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas
    Nicolas Girard
    Human Oncology and Pathogenesis Program HOPP, Weill Medical College of Cornell University, New York, New York, USA
    Clin Cancer Res 15:6790-9. 2009
    ..However, whether the underlying biology of these tumors warrants such clustering is unclear, and the optimum treatment of either entity is unknown...
  75. ncbi Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems
    Hsuan-Ying Huang
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Hum Pathol 35:612-21. 2004
    ..However, DSM rate is significantly related to tumor necrosis, large size, and decreased myxoid area. Tumors having necrosis or exceeding 5 cm are at significant risk of metastatic relapse...
  76. ncbi Clinicopathologic correlates of solitary fibrous tumors
    Jason S Gold
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Cancer 94:1057-68. 2002
    ..Most SFT patients fare well after surgical treatment. Closer surveillance is warranted for those tumors that are larger than 10 cm or with the presence of a histologically malignant component...
  77. ncbi Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
    Ronald P Dematteo
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet 373:1097-104. 2009
    ..We postulated that adjuvant treatment with imatinib would improve recurrence-free survival compared with placebo after resection of localised, primary gastrointestinal stromal tumour...
  78. ncbi Classification and subtype prediction of adult soft tissue sarcoma by functional genomics
    Neil H Segal
    Swim Across America Laboratory, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York and Columbia Genome Center, Columbia University, New York, New York 10021, USA
    Am J Pathol 163:691-700. 2003
    ..In conclusion, we showed gene expression profiling to be useful in classification and diagnosis, providing insights into pathogenesis and pointing to potential new therapeutic targets of soft tissue sarcoma...
  79. ncbi Low-grade myxofibrosarcoma: CT and MRI patterns in recurrent disease
    Brendan Waters
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    AJR Am J Roentgenol 188:W193-8. 2007
    ..Knowledge of these unusual characteristics is important in assessing the presence and extent of recurrent low-grade myxofibrosarcoma before surgical reexcision...
  80. ncbi Midline carcinoma of children and young adults with NUT rearrangement
    Christopher A French
    Department of Pathology, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    J Clin Oncol 22:4135-9. 2004
    ..We sought to amass a more definitive series of tumors with NUT and/or BRD4 gene rearrangements and to determine distinct clinicopathologic features...
  81. ncbi PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21)
    Pedram Argani
    Department of Pathology, Surgical Pathology, Johns Hopkins Hospital, Weinberg Building, Room 2242, 401 N Broadway, Baltimore, MD 21231 2410, USA
    Am J Surg Pathol 26:1553-66. 2002
    ..Aside from their distinctive clinicopathologic features described here, there is experimental evidence suggesting that these tumors may show differential sensitivity to certain chemotherapeutic agents...
  82. ncbi Epithelioid variant of pleomorphic liposarcoma: a comparative immunohistochemical and ultrastructural analysis of six cases with emphasis on overlapping features with epithelial malignancies
    Hsuan-Ying Huang
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Ultrastruct Pathol 26:299-308. 2002
    ..Despite some overlapping features, electron microscopy remains a useful tool to distinguish between epithelioid PL and ACC...
  83. ncbi Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma. A study of interobserver agreement
    K J Busam
    Dept of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Am J Clin Pathol 115:856-60. 2001
    ..75). These findings suggest that the categorization of TILs can be easily taught and can be applied with an acceptable level of reproducibility in routine diagnostic practice...
  84. ncbi Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes
    Janice N Cormier
    Sarcoma Center and Department of Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA
    J Clin Oncol 22:4567-74. 2004
    ..These results suggest that caution should be used in the interpretation of randomized clinical trials of adjuvant chemotherapy that seem to demonstrate clinical benefits with relatively short-term follow-up...
  85. ncbi Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene
    Fredrik Mertens
    Department of Clinical Genetics, Lund University Hospital, Lund, Sweden
    Lab Invest 85:408-15. 2005
    ..Taken together, the results indicate that virtually all LGFMS are characterized by a chimeric FUS/CREB3L2 gene, and that rare cases may display a variant FUS/CREB3L1 fusion...
  86. ncbi Gene expression profiling of human sarcomas: insights into sarcoma biology
    Kristin Baird
    Cancer Genetics Branch, National Human Genome Research Institute
    Cancer Res 65:9226-35. 2005
    ..nhgri.nih.gov/sarcoma), allowing the user to interactively explore this data set in depth...
  87. ncbi Prognostic factors for survival in patients with locally recurrent extremity soft tissue sarcomas
    Fritz C Eilber
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 12:228-36. 2005
    ..A large local recurrence that develops in a short interval indicates a biologically aggressive tumor with a high tumor-specific mortality. Patients who develop such recurrences are ideal subjects for systemic neoadjuvant therapy trials...
  88. ncbi Atypical lipomatous tumor/well-differentiated liposarcoma of the extremity and trunk wall: importance of histological subtype with treatment recommendations
    David A Kooby
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 11:78-84. 2004
    ..Margin-positive sclerosing WDLSs have a 10-year LRFS of only 17% and should undergo function-preserving re-excision when possible, or adjuvant radiotherapy...
  89. ncbi Congenital and childhood plexiform (multinodular) cellular schwannoma: a troublesome mimic of malignant peripheral nerve sheath tumor
    James M Woodruff
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Am J Surg Pathol 27:1321-9. 2003
    ..These features may lead to a misdiagnosis of malignancy, which could result in harmful overtreatment...
  90. ncbi TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies
    Jefferson Terry
    Genetic Pathology Evaluation Centre, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E6
    Am J Surg Pathol 31:240-6. 2007
    ..Our findings establish TLE as a robust immunohistochemical marker for synovial sarcoma, and may have implications for understanding the biology of synovial sarcoma and for developing experimental therapies for this cancer...
  91. ncbi Monophasic sarcomatoid carcinoma of the scalp: a case mimicking inflammatory myofibroblastic tumor and a review of cutaneous spindle cell tumors with myofibroblastic differentiation
    Harry L Winfield
    Tulane University Health Sciences Center, New Orleans, LA, USA
    J Cutan Pathol 30:393-400. 2003
    ..The nomenclature of these spindle cell tumors is discussed...
  92. ncbi Inconspicuous insertion 22;12 in myxoid/round cell liposarcoma accompanied by the secondary structural abnormality der(16)t(1;16)
    Nathan C Birch
    Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA
    J Mol Diagn 5:191-4. 2003
    ....
  93. ncbi Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation
    Susanne V Allander
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA
    Am J Pathol 161:1587-95. 2002
    ....
  94. ncbi An expression signature classifies chemotherapy-resistant pediatric osteosarcoma
    Michelle B Mintz
    Neurogenomics Division and Genetic Basis of Human Disease Division, Translational Genomics Research Institute, Phoenix, Arizona 85004, USA
    Cancer Res 65:1748-54. 2005
    ..We propose that osteosarcoma tumor-driven changes in the bone microenvironment contribute to the chemotherapy-resistant phenotype and offer testable hypotheses to potentially enhance therapeutic response...